美发现预测前列腺癌预后不良的新指标

 
根据在2005年10月美国丹佛举行的美国治疗性放射学和肿瘤学年度会议上报道的一项研究结果，研究人员已经鉴别出一种能够提示生长迅速的前列腺癌生物指标。

值得关注的是一种叫做MDM2的蛋白质，研究人员发现这种蛋白质是癌瘤将向前列腺腺体外转移的强烈而独立的预测因子， 提示死于该疾病的危险增加。这项研究包括469例接受短期和长期男性激素剥夺治疗和放疗的患者。中位数随访时间为70.5个月，在前列腺组织中进行免疫组化检查，以检测癌组织中的癌细胞。

尽管其他一些生物指标被发现与生物化学功能障碍、癌瘤远处转移、总体死亡率相关，但是MDM2与所有这三种预后持续相关。总体而言，MDM2出现后远处癌瘤转移发生率增加1倍(10-20%)，5年生存率下降10%。
 
Biomarker for Aggressive Prostate Cancer
 
Researchers have identified a biomarker that indicates a more-aggressive form of prostate cancer, according to a study presented at the annual meeting of the American Society for Therapeutic Radiology and Oncology in Denver (CO) in October 2005.

Specifically, a protein called MDM2 was found to be a strong and independent predictor that the prostate cancer will metastasize beyond the prostate gland, indicating an increased risk of death from the disease. The study involved 469 men treated with short- and long-term androgen deprivation therapy and radiation. The median follow-up was 70.5 months, when an immunohistochemical analysis was conducted on prostate tissue to determine the amount of MDM2 in the prostate cancer cells.

Although other biomarkers were found to be associated with biochemical failure, distant metastasis, or overall mortality, MDM2 was consistently associated with all three outcomes. Overall, MDM2 was associated with a doubling of distant metastasis (10-20%) and a nearly 10% reduction in five-year survival.